Drug · Small Molecule

Etoposide

CI-DRUG-00000225Explore in graph →NCIt C491 CHEMBL44657 CIViC Approved

Regulatory

Approvals (18)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory18 approval records from 2 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as ETOPOSIDE INJECTION (DIN 02552671) under ATC L01CB01 ETOPOSIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jun 20, 2025	health-canada-dpd
CA Health Canada	—	Marketed in Canada as ETOPOSIDE INJECTION (DIN 02239961) under ATC L01CB01 ETOPOSIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Aug 3, 2017	Oct 20, 2014	health-canada-dpd
CA Health Canada	—	Marketed in Canada as ETOPOSIDE INJECTION, USP (DIN 02422530) under ATC L01CB01 ETOPOSIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormant

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 18 hours agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	239	110	283	1,194	18	CA, US	Dec 31, 1984	1988-03
Malignant Lung Neoplasm	Approved	Phase 4	58	25	51	219	3	US	Dec 30, 1986	1993-01
Malignant Testicular Neoplasm	Approved	Phase 3	2	1	3	10	1	US	Feb 13, 2026	Nov 3, 2003
Non-Hodgkin Lymphoma	Phase4	Phase 4	48	20	30	200	0

Curated evidence

Clinical evidence (10)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–10 of 10 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
NPM1 W288FS1
Cytarabine + Daunorubicin

Clinical trials

Trials with this intervention (1,197)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 1,197 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00092222	Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity	active not recruiting	Phase 2	75	National Cancer Institute (NCI)NIH	1	Sep 28, 2026	clinicaltrials
NCT03418038	Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Molecule

Record

Kind: Small Molecule
Mechanism: DNA topoisomerase II inhibitor
Targets: 2 genes
UNII: 6PLQ3CP4P3
Aliases: 4'-Demethylepipodophyllotoxin 9-[4,6-O-ethylidene-beta-D-glucopyranoside], 9-[(4,6-O-Ethylidene-beta-D-glucopyranosyl]oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, AVOPEF, Demethyl Epipodophyllotoxin Ethylidine Glucoside, DOM-ETOPOSIDE, EPEG, EPOSIN, ETOPOPHOS, Etoposide, Etoposide resolution mixture, Etoposido, Etoposidum, Lastet, NSC-141540, PMS-ETOPOSIDE, Sintopozid, Toposar, Vepesid, VEPESID, VP 16, VP16, VP 16-213, VP 16213, VP-16-213, VP16213

Data updated 21 hours agoSource updated unknown

Identifiers

Codes (27)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01CB01	ETOPOSIDE
DIN (Health Canada)	00523410

TOP2A TOP2A/902
Etoposide	Leukemia	Predictive	D	Supports Resistance	4	submitted	EID9634 In an in vitro study, leukemia cells expressing TOP2A/90 show increased inhibition (p < 0.025) upon KD of TOP2A/90 when treated with etoposide. Moreover cells expressing TOP2A/170 but not TOP2A/90 sho… (full text at CIViC) PMID 29514855 · Kanagasabai et al., 2018 · Open in CIViC	civic
4'-(9-acridinylamino)methanesulfon-m-anisidide + DVP Regimen + Etoposide + MVT Regimen + PixantroneSubstitutes	Leukemia	Predictive	D	Supports Resistance	4	submitted	EID9635 In an in vitro study, leukemia cells expressing TOP2A/90 show increased IC50 compared to leukemia cells underexpressing TOP2A/90 when treated with etoposide, daunorubicin, mAMSA, mitoxantrone and pixa… (full text at CIViC) PMID 33446509 · Hernandez et al., 2021 · Open in CIViC	civic